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Abstract
Mixed infections are one of the major therapeutic challenges, as the current strategies have had limited success. One of the
most common and widespread conditions of mixed infection is respiratory syncytial virus-mediated pathology of the
respiratory tract in children. There is a dire need for the development of novel therapeutic approaches during mixed
infections. Therapeutic intravenous immunoglobulin preparations, obtained from plasma pools of healthy donors have
been used in immune deficiencies. This study was thus designed to characterize the functional efficacy of RSV-specific
antibodies in IVIg. To explore the functional ability of these affinity-purified RSV-specific antibodies, the antibody-
dependent and complement dependent cytotoxicity was determined using peripheral cells of healthy donors. This study
demonstrates the existence of highly potent RSV-specific antibodies in IVIg preparations and provides the basis for the use
of IVIg as broad-spectrum protective shield to RSV-infected children during mixed infections.
Citation: Gupta N, LeGoff J, Chamat S, Mercier-Delarue S, Touzelet O, et al. (2013) Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous
Immunoglobulin Exert Potent Antibody-Dependent Cellular Cytotoxicity. PLoS ONE 8(7): e69390. doi:10.1371/journal.pone.0069390
Editor: Jean Kanellopoulos, University Paris Sud, France
Received January 18, 2012; Accepted June 14, 2013; Published July 19, 2013
Copyright:  2013 Gupta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was Supported by Institut National de la Sante´ et de la Recherche Me´dicale, Universite´ Pierre et Marie Curie, Universite´ Paris Descartes;
Centre National de la Recherche Scientifique; European Community’s Seventh Framework Programme [FP7-2007–2013]-HEALTH-F2-2010-260338-ALLFUN. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for
this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: srini.kaveri@crc.jussieu.fr
Introduction
The Respiratory syncytial virus (RSV) is a common and
widespread respiratory tract infectious agent. RSV usually induces
a benign infection in immunocompetent individuals, [1] but is the
most important cause of bronchiolitis and pneumonia in infants
and young children [2,3]. Currently, there is no effective vaccine
available to prevent RSV infection. Although anti-viral drugs are
proposed to treat RSV infections, their efficacy in children is
debatable. RespiGamH, a preparation of pooled normal immu-
noglobulins that contains high titer antibodies against RSV was
utilized as an alternative immunoprophylactic approach [4]. The
emergence of highly specific monoclonal antibodies such as
Palivizumab and Motavizumab, led to the withdrawal of
RespiGamH from the market. However, the cost and the agent-
specific nature of the monoclonal antibodies warrant the search for
a safer and broad-spectrum immunoprophylactic alternative.
Intravenous immunoglobulin G (IVIg) is a preparation obtained
from plasma pools of several thousand healthy blood donors and is
used to treat various autoimmune, infectious, and idiopathic
diseases [5,6]. The content of antibodies against microbial antigens
is influenced by the endemic nature of the pathogens and
vaccination history of the population. Several studies have
documented the existence of antibodies against pathogens
including West Nile Virus, hepatitis B virus, cytomegalovirus
and Plasmodium [7–12]. The current study was thus designed to
determine the presence of RSV-specific antibodies and their
functional potency after antigen-specific purification in various
commercially available IVIg preparations.
Materials and Methods
Ethics Statement
Buffy bags from healthy donors were obtained after written
consent following the approval by ethical committees of Institut
national de la sante´ et de la recherche me´dicale (INSERM) and
Etablissement Franc¸ais du Sang (EFS), Paris, France; convention
12/EFS/079.
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Virus and Cells
RSV A strain Long was employed throughout this study and
was a kind gift from Dr. Sabine Riffault (UR892, INRA, Jouy-en-
Josas, France). The Human HEp-2 cells were obtained from the
European cell culture collection and maintained in minimum
essential medium (MEM) with Earle’s salts supplemented with
2 mM L-glutamine and 10% fetal bovine serum. Human
peripheral blood mononuclear cells (PBMC) were isolated from
whole blood of healthy donors by centrifugation on a Ficoll-Paque
layer (PAA, Velizy-Villacoublay). PBMCs were depleted of CD4+
T cells by positive selection using CD4 microbeads (Miltenyi
Biotec).
Purification of Anti-RSV Antibodies from Intravenous
Immunoglobulin
Recombinant RSV G protein (Sino Biological Inc.) was coupled
to CNBr-activated CH Sepharose 4B (Pharmacia) according to the
manufacturer’s instructions. IVIg was incubated with the affinity
matrix overnight at 4uC. After washing the column with PBS until
the effluent was protein-free, the bound fraction was eluted with a
0.2M glycine-HCl buffer pH 2.8 and the eluate was immediately
neutralized with 4M Tris. The eluate was dialyzed against PBS
and concentrated using Amicon Ultra centrifugal filters (Milli-
pore).
ELISA
MaxiSorpH microtiter plates (Nunc, Denmark) were coated with
Recombinant G protein of RSV (2 mg/ml) in PBS by incubating
for 2 h at room temperature (RT). The unbound sites were
blocked using 0.25% Tween-20 in PBS for 2 h at RT. The plates
Figure 1. Reactivity of native IVIg and purified anti-RSV G
antibodies. A) Reactivity of various IVIg preparations (labeled P1 to
P9) with the recombinant G protein of RSV. B) Reactivity of IVIg (line
with circle) and affinity-purified anti-RSV IgG (line with square) with the
recombinant G protein of RSV.
doi:10.1371/journal.pone.0069390.g001
Figure 2. Antibody-dependent cell-mediated cytotoxicity
(ADCC) activity. The RSV infected Hep-2 cells were used as target
cells and PBMCs were used as effector cells. The cells were incubated
with various concentrations of IVIg (line with circle), anti-RSV G IgG (line
with square) and anti-RSV F IgG (line with blank circle). The assay was
performed at the ratio of 50:1 (Effector: Target) in triplicates. Data were
analyzed by two-way ANOVA followed by Bonferroni test for
comparison between IVIg, anti-RSV G IgG and anti-RSV F IgG treated
cells. Results are mean6 standard error of the mean of values obtained
with PBMCs (effector cells) from 6 individual donors in three
independent experiments. ***P,0.001, and *P,0.05.
doi:10.1371/journal.pone.0069390.g002
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were incubated with serial dilutions of different preparation of
IVIg or affinity purified anti-RSV G antibodies (diluted in 0.05%
Tween-20-PBS) for 2 h at RT. The plates were washed and
incubated with horseradish peroxidase conjugated Goat anti-
human IgG antibodies (Southern Biotech). Bound antibodies were
revealed and the optical density was determined at 490 nm using
an Emax ELISA reader (Molecular Devices, Menlo Park, CA).
Antibody-dependent Cellular Cytotoxicity (ADCC)
The ADCC activity of the affinity purified anti-RSV G
antibodies, anti-RSV F monoclonal antibody (MAb) (Palivizumab)
and IVIg was assessed using CytoTox 96 non-radioactive
cytotoxicity assay kit (Promega, France). The PBMCs (effector
cells) were resuspended in X-VIVO 15 medium (Lonza, Switzer-
land) and incubated overnight at 37uC in the presence of 100 ng/
ml recombinant human IL-2 (Miltenyi Biotec, France). HEp-2
cells (target cells) were infected with RSV at 0.5 MOI for 24 h.
The cells were washed and resuspended in assay buffer {RPMI-
1640 (Lonza, Switzerland) supplemented with 5% FBS (Hyclone,
UK), 15 mM HEPES (Invitrogen, France)} at a density of 26105
cells/ml. The HEp-2 cells were distributed into round-bottomed
96-well plates (50 ml/well) along with various concentrations of
IVIg, affinity purified anti-RSV-G antibodies and anti-RSV F
MAb at 50 ml/well in assay buffer (without FBS) and the mixtures
were incubated at 37uC for 30 minutes. The IL-2 stimulated and
non-adherent PBMCs were then harvested and resuspened in the
assay buffer at the density of 56106 cells/ml and added at 100 ml/
well to the assay plates (effector: target ratio of 50:1). The assay
controls were prepared as per the protocol of cytotoxicity assay kit.
The plates were centrifuged at 2506g for 4 minutes and incubated
at 37uC for 4 h. For target cell maximum LDH release control, the
lysis solution was added to the corresponding wells 45 min prior to
the completion of incubation and the plates were centrifuged at
2506g for 4 minutes. After complete incubation, 50 ml of
supernatant from each well was transferred to flat-bottom
MaxiSorp 96-well plates. 50 ml of reconstituted substrate mix
was then added to all wells and plates were incubated in the dark
at RT for 30 min. 50 ml of stop solution was added to all wells and
LDH release was quantified by measuring the absorbance at
490 nm. The experiment was performed in triplicates. The culture
medium background absorbance was subtracted from all test or
control absorbance values and the percentage of cytotoxicity was
calculated using the following formula:
% Cytotoxicity~
(Experimental{Effector Spon tan eous{T arg et Spon tan eous)
7 (T arg et Maximum{T arg et Spon tan eous)|100
Experimental corresponds to the absorbance obtained in assay
conditions including both target cells and effector cells with serially
diluted antibodies. Effector spontaneous corresponds to the absor-
bance obtained in the presence of PBMCs alone, Target spontaneous
corresponds to the absorbance obtained in the presence of HEp-2
cells alone and Target maximum corresponds to the absorbance
obtained in the presence of detergent-lysed HEp-2 cells.
Complement-dependent Cytotoxicity (CDC)
The CDC activity of the affinity purified anti-RSV G
antibodies, anti-RSV F MAb and IVIg was assessed using
CytoTox 96 non-radioactive cytotoxicity assay kit (Promega,
France) with some modifications. Briefly, HEp-2 cells were
infected with RSV at 0.5 MOI for 24 h followed by washing
and resuspended in assay buffer (see above) at a density of 26105
cells/ml. The HEp-2 cells were distributed in round-bottomed 96-
well plates (50 ml/well) along with various concentrations of IVIg,
affinity purified anti-RSV-G antibodies and anti-RSV F antibodies
at 50 ml/well in assay buffer (without FBS) and the mixtures were
incubated at 37uC for 30 min. Rabbit complement sera (Sigma)
was diluted in RPMI-1640 (1:12) and added at 100 ml/well to the
assay plates followed by incubation for 90 min at 37uC. The assay
controls were prepared as per the manufacturer’s instructions and
the culture medium with rabbit complement sera was used as an
additional assay control to correct background absorbance. The
percentage of cytotoxicity was determined using following
formula:
%Cytotoxicity~(Experimental{T arg et Spon tan eous)
7 (T arg et Maximum{T arg et Spon tan eous)|100:
Statistical Analysis
The differences between groups were compared using Two-
Way ANOVA followed by Bonferroni test, utilyzing GraphPad
Prism Software (San Diego California USA). Data were presented
as mean 6 standard error of values obtained in three independent
experiments.
Figure 3. Complement-dependent cytotoxicity (CDC) activity.
The RSV infected Hep-2 cells were used, as target cells and rabbit
complement serum was the source of complement. The cells were
incubated with various concentrations of IVIg (line with circle), anti-RSV
G IgG (line with square) and anti-RSV F IgG (line with blank circle), in
triplicates. Data were analyzed by two-way ANOVA followed by
Bonferroni test for comparison between IVIg, anti-RSV G IgG and anti-
RSV F IgG treated cells. Results are mean 6 standard error of values
obtained in three independent experiments. ns: non-significant.
doi:10.1371/journal.pone.0069390.g003
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Results and Discussion
Several studies have proposed the crucial role of RSV G protein
in RSV-mediated pathology and therapeutic as well as prophy-
lactic targeting of this glycoprotein has been anticipated to be
beneficial [13–18]. In the present study, we thus focused on the
antibodies against this important protein of RSV [19,20].
Ten different commercial IVIg preparations including Respi-
GamH were analyzed for their capacity to bind to a recombinant
G protein of RSV. We observed that all tested IVIg preparations
recognize recombinant G protein of RSV, but these preparations
have varying proportion of the specific antibodies (Figure 1A). To
characterize the RSV G-reactive antibodies, we affinity purified
anti-RSV G antibodies from one of the IVIg preparations, using
recombinant RSV G protein coupled to CNBr-activated CH
Sepharose 4B. We observed that approximately 0.15% of the
loaded IVIg bound to the affinity column. This affinity-purified
anti-RSV IgG recognized RSV G protein at 100-fold lower
concentrations than the unfractionated total IVIg (Figure 1B).
The functional potency of affinity-purified anti-RSV antibodies
was examined by their ability to mediate antibody-dependent
cytotoxicity of HEp-2 cells infected with RSV [21]. Results show
that affinity-purified anti-RSV G antibodies mediate a potent
ADCC towards RSV-infected HEp-2 cells in a dose-dependent
manner (52.17%64.6 at 100 mg/ml; 30.69%63.5 at 33.33 mg/
ml; 13.1664.2 at 11.1 mg/ml; 3.9%61.05 at 3.7 mg/ml and
2.19%60.5 at 1.2 mg/ml). The unfractionated total IVIg also
showed ADCC towards RSV-infected HEp-2 cells at higher
concentrations (13.43%62 at 100 mg/ml; 6.48%62.8 at
33.33 mg/ml; 1.7361.23 at 11.1 mg/ml; 0.35%60.35 at 3.7 mg/
ml and 0%60.5 at 1.2 mg/ml). The ADCC observed in the
presence of anti-RSV F MAb (11%63.6 at 100 mg/ml; 4%61.4
at 33.33 mg/ml; 1.360.74 at 11.1 mg/ml; 0.89%60.58 at 3.7 mg/
ml and 0%60.5 at 1.2 mg/ml) was even lower than the ADCC
exerted by unfractionated IVIg (Figure 2). However, affinity-
purified anti-RSV G antibodies were 4 to 8-fold more potent than
unfractionated total IVIg or anti-RSV F MAb in attaining
significant lysis (Figure 2). The possible involvement of ADCC
by anti-RSV-G antibodies in the virus clearance has been
proposed [17,18] and our results confirms that anti-RSV G
antibodies purified from the IVIg preparation have the potential to
exert ADCC. The low ADCC by anti-RSV F MAb in our
experiments suggest that ADCC is not an important effector
function of this antibody [22].
To extend our observations regarding the functional potency of
these antibodies we further analyzed their efficiency for comple-
ment-dependent cytotoxicity of HEp-2 cells infected with RSV.
These antibodies were unable, however, to mediate efficient
complement-dependent lysis of RSV-infected HEp-2 cells
(Figure 3). The absence of complement-dependent cytotoxicity
could be associated with the manufacturing process of IVIG
preparations [23].
Conclusion
This study clearly demonstrates that in addition to previously
identified pathogen-specific antibodies; IVIg also contains anti-
bodies against RSV. The presence of anti-RSV antibodies in IVIg
is undoubtedly related to the wide spread prevalence of the virus
across the globe. Functionally potent RSV-specific antibodies can
be concentrated from IVIg by using affinity chromatography.
These concentrated antibodies display higher functional potency
than native preparations. Mixed types of infections are common in
children infected with RSV [24]. MAbs that are highly specific for
RSV cannot control mixed infections in susceptible patients. In
this context, IVIg has an advantage as it contains antibodies to
large number of viral and bacterial pathogens including RSV and
can provide broad-spectrum protective shield to RSV-infected
patients. This information can be utilized to artificially enrich
immunoglobulin preparations for the prophylaxis of mixed
infections. However, the low yield of affinity-purified antibodies
may limit the preparation process of such specialized products.
This can be overcome by enriching the IVIg preparations by
addition of monoclonal anti-RSV G MAbs with defined effector
functions. The limitation of our study is not being able to extend
our observation in the PBMCs from pediatric subjects because of
the ethical issues in obtaining the blood samples. It is likely that
pediatric subjects and adults may show variation in the magnitude
of ADCC. However, it has been illustrated that ADCC by
neonatal cells is comparable to that of adults [25] and can be
further enhanced by pharmacologic means [25,26]. Taken
together, we believe that this report provides the basis for future
studies on immunoglobulin prophylaxis against mixed infections.
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